Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine

BACKGROUND: Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428) to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Goh, Gerald, Schmid, Ramona, Guiver, Kelly, Arpornwirat, Wichit, Chitapanarux, Imjai, Ganju, Vinod, Im, Seock-Ah, Kim, Sung-Bae, Dechaphunkul, Arunee, Maneechavakajorn, Jedzada, Spector, Neil, Yau, Thomas, Afrit, Mehdi, Ahmed, Slim Ben, Johnston, Stephen R., Gibson, Neil, Uttenreuther-Fischer, Martina, Herrero, Javier, Swanton, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140058/
https://www.ncbi.nlm.nih.gov/pubmed/27923043
http://dx.doi.org/10.1371/journal.pmed.1002136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140058/
https://www.ncbi.nlm.nih.gov/pubmed/27923043
http://dx.doi.org/10.1371/journal.pmed.1002136

Ejemplares similares